The details of these notes and other loans and contingent liabilities are as follows:

									Fixed
								Conversion	Rate
Lender	1st-Issue	Principal		Duration		Interest		Price	EUR/USD
Price	Date	Amount		(Note)		Rate		(stated)	Conversion

Norwood Secured Loan	04/03/2009	E	2,500	(5	)	10% pa	$	None (8)	N/A
Eardley Holding A.G. (1)	06/23/2006	E	144	(2	)	10% pa	$	US 0.10	N/A
Anglo Irish Bank S.A.(3)	10/21/2007	E	500	(2	)	10% pa	$	US 0.50	1.4090
Round Enterprises Ltd.	12/10/2007	E	1,500	(2	)	10% pa	$	US 0.50	1.4429
Round Enterprises Ltd.	01/22/2008	E	1,500	(2	)	10% pa	$	US 0.50	1.4629
Round Enterprises Ltd.	04/25/2008	E	2,000	(2	)	10% pa	$	US 0.50	1.5889
Round Enterprises Ltd.	06/30/2008	E	1,500	(2	)	10% pa	$	US 0.50	1.5380
Round Enterprises Ltd.	11/18/2008	E	1,200	(2	)	10% pa	$	US 0.50	1.2650
Round Enterprises Ltd.	02/09/2009	E	1,500	(2	)	10% pa	$	US 0.50	1.2940
Round Enterprises Ltd.	06/15/2009	E	5,500	(2,4	)	10% pa	$	US 0.80	1.4045
Eardley Holding A.G.	06/15/2009	E	100	(2,4	)	10% pa	$	US 0.80	1.4300
Von Meyenburg	08/03/2009	E	200	(2	)	10% pa	$	US 0.80	1.4400
Round Enterprises Ltd.	10/13/2009	E	2,000	(2	)	5% pa	$	US 0.25	1.4854
Round Enterprises Ltd.	12/18/2009	E	2,200	(2	)	5% pa	$	US 0.25	1.4338
Round Enterprises Ltd.	08/04/2011	E	910	(2,7	)	10% pa		None (8)	N/A
Eardley Holding A.G.	08/04/2011	E	227	(2,7	)	10% pa		None (8)	N/A
Round Enterprises Ltd.	11/08/2011	E	400	(2	)	10% pa		None (8)	N/A
Eardley Holding A.G.	11/08/2011	E	100	(2	)	10% pa		None (8)	N/A
Round Enterprises Ltd.	02/10/2012	E	1,000	(2	)	10% pa		None (8)	N/A
Eardley Holding A.G.	02/14/2012	E	200	(2	)	10% pa		None (8)	N/A
Round Enterprises Ltd.	04/19/2012	E	321	(2	)	10% pa		None (8)	N/A
Eardley Holding A.G.	04/19/2012	E	81	(2	)	10% pa		None (8)	N/A
Round Enterprises Ltd.	05/04/2012	E	480	(2	)	10% pa		None (8)	N/A
Eardley Holding A.G.	05/04/2012	E	120	(2	)	10% pa		None (8)	N/A
Round Enterprises Ltd.	09/03/2012	E	200	(2	)	10% pa		None (8)	N/A
Eardley Holding A.G.	09/03/2012	E	50	(2	)	10% pa		None (8)	N/A
Round Enterprises Ltd.	11/14/2012	E	500	(2	)	10% pa		None (8)	N/A
Eardley Holding A.G.	12/06/2012	E	125	(2	)	10% pa		None (8)	N/A
Total Short Term Principal Amounts		E	27,058
Accrued Interest		E	7,665
Total Convertible Notes to Related Parties		E	34,723
Norwood Contingent Liability		E	6,533	(6	)

TOTAL LOANS, NOTES,AND CONTINGENT LIABILITY		E	41,256

(1) Private investment company of Dr. Thomas Staehelin, member of the Board of Directors and of the Audit Committee of the Company. Face value is stated in U.S. dollars at $190.

(2) This maturity date is automatically prolonged for periods of 3 months, unless called for repayment. The conversion price is determined by reducing by 10% the price per share of the Company's common stock paid by the investors in connection with an investment in the Company of not less than $20,000,000. The loan is secured against IP assets of Mymetics Corporation.

(3) Renamed Hyposwiss Private Bank Geneve S.A. and acting on behalf of Round Enterprises Ltd. which is a major shareholder.

(4) The loan is secured against 2/3rds of the IP assets of Bestewil Holding BV.

(5) Under the terms of the acquisition of Bestewil BV, as part of the consideration, the Company issued to Norwood Immunology Limited ("NIL") a convertible redeemable note (the "Note") in the principal amount of E2,500 with a maturity date of March 31, 2013 and bearing interest at 10% per annum. The note is secured against 1/3rd of Bestewil common stock. Management is under negotiation with NIL. The repayment of the loan will be half in shares and half in cash and is contingent on an investment in the Company of not less than $20,000 by new investors.

(6) Under the terms of the acquisition of Bestewil BV, as part of the consideration, the Company is committed to make further payments to NIL in the event that certain stated milestones for the development of vaccines are achieved. These have been considered on a risk probability basis.

(7) The face values of the loans are stated in U.S. dollars at $1,200 and $300, respectively.

(8) The conversion feature is contingent on an investment in the Company of not less than $20,000. The conversion price is determined by reducing by 10% the price per share of the Company's common stock paid by the investors in connection with such an investment.